2010-2014年美国耐甲氧西林金黄色葡萄球菌与甲氧西林敏感金黄色葡萄球菌住院相关全国费用分析
该研究基于2010-2014年美国全国住院患者样本进行回顾性分析,比较MRSA与MSSA相关败血症、肺炎及其他感染的住院费用。倾向评分校正后,MSSA相关肺炎费用显著高于MRSA相关肺炎(40725美元 vs 38561美元,P=.045),MSSA相关其他感染费用也显著更高(15578美元 vs 14792美元,P<.001)。MRSA相关住院的校正死亡率仍高于MSSA相关住院。
要点
- 2014年MSSA相关肺炎住院校正费用显著高于MRSA相关肺炎(40725美元 vs 38561美元,P=.045)。
- MSSA相关其他感染住院校正费用显著高于MRSA相关其他感染(15578美元 vs 14792美元,P<.001)。
- MRSA相关住院的校正死亡率仍高于MSSA相关住院。
核心结论
- 近年来MSSA相关感染费用已与MRSA相关住院费用趋同,并可能超过MRSA相关住院费用。
- MRSA相关住院的校正死亡率仍高于MSSA相关住院。
研究设计与样本
- 回顾性分析,数据来自美国医疗保健研究与质量局全国住院患者样本,年份为2010-2014年。
- 计算MRSA和MSSA相关败血症、肺炎及「其他感染」的住院费用。
- 采用倾向评分校正死亡率结局估算住院费用差异。
主要发现
- 2014年肺炎和脓毒症相关住院的估算费用最高。
- 倾向评分校正后,MSSA相关肺炎住院费用为40725美元 vs MRSA相关肺炎38561美元(P=.045)。
- 倾向评分校正后,MSSA相关其他感染住院费用为15578美元 vs MRSA相关其他感染14792美元(P<.001)。
- 2010至2013年观察到相似模式;MSSA与MRSA相关肺炎住院的粗费用差异从2010年的25.8%上升至2014年的31.0%。
- 与MSSA相关住院相比,MRSA相关住院的校正死亡率更高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Infections caused by methicillin-resistant Staphylococcus aureus (MRSA) have been associated with worse patient outcomes and higher costs of care than methicillin-susceptible (MSSA) infections. However, since prior studies found these differences, the healthcare landscape has changed, including widespread dissemination of community-associated strains of MRSA. We sought to provide updated estimates of the excess costs of MRSA infections. METHODS: We conducted a retrospective analysis using data from the National Inpatient Sample from the Agency for Healthcare Research and Quality for the years 2010-2014. We calculated costs for hospitalizations, including MRSA- and MSSA-related septicemia and pneumonia infections, as well as MRSA- and MSSA-related infections from conditions classified elsewhere and of an unspecified site ("other infections"). Differences in the costs of hospitalization were estimated using propensity score-adjusted mortality outcomes for 2010-2014. RESULTS: In 2014, estimated costs were highest for pneumonia and sepsis-related hospitalizations. Propensity score-adjusted costs were significantly higher for MSSA-related pneumonia ($40725 vs $38561; P = .045) and other hospitalizations ($15578 vs $14792; P < .001) than for MRSA-related hospitalizations. Similar patterns were observed from 2010 to 2013, although crude cost differences between MSSA- and MRSA-related pneumonia hospitalizations rose from 25.8% in 2010 to 31.0% in 2014. Compared with MSSA-related hospitalizations, MRSA-related hospitalizations had a higher adjusted mortality rate. CONCLUSIONS: Although MRSA infections had been previously associated with higher hospitalization costs, our results suggest that, in recent years, costs associated with MSSA-related infections have converged with and may surpass costs of similar MRSA-related hospitalizations.
引用
- Klein EY, Jiang W, Mojica N, et al. National Costs Associated With Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Hospitalizations in the United States, 2010-2014. Clin Infect Dis. 2019. PMID: 29762662. doi:10.1093/cid/ciy399
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。